Welcome!

News Feed Item

US Excipients Market



 

 

 

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:



US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html


US demand to grow 4.3% annually through 2018

Demand for pharmaceutical excipients in the US is projected to rise 4.3 percent per year to $2.0 billion in 2018. In volume terms, demand is expected to grow 1.9 percent annually to 900 million pounds over the same period. While continued growth in pharmaceutical output will be the primary driver of increases in excipient demand, gains will accelerate as excipients play a larger role in bringing additional value to pharmaceutical products by improving properties such as the controlled release or improved
absorption of active ingredients.


Preservatives, suspension agents to see strong gains

Trends in pharmaceutical output by dosage formulation will have a strong influence on excipient demand by application. Output of parenteral preparations is expected to rise at an especially strong pace through 2018, supporting demand for suspension agents and preservatives. Solvents are also projected to benefit from increased shipments of parenteral drugs, although gains in dollar terms will be limited by the continued decline in glycerin prices due to oversupply.
Oral preparations are the largest category of pharmaceutical dosage formulations; thus, oral pharmaceuticals tend to require more excipients than other types of drugs and have a significant impact on excipient demand. Shipments of oral pharmaceuticals are forecast to rise at a faster pace than seen in the 2008-2013 period, supporting accelerated gains in demand for fillers, binders, coatings, flavoring agents, capsules, and disintegrants. In addition, oral formulations such as delayed- and extended-release tablets and capsules and dissolving tablets are expected to boost their market share, further raising demand for excipients such as binders and disintegrants.


Specialty excipient blends to add value to product mix

A major development in the excipient and pharmaceutical industries is the increased dependence on specialty excipient blends. Specialty excipient blends can add value to pharmaceutical products by differentiating them from competitive products, and by optimizing the production process. These value-added excipient blends are often formulated for usage in specific manufacturing processes such as direct compression or wet granulation, and are optimized for certain performance characteristics such as delayed- or extended-release oral tablets. Product differentiation will play an increasingly important role going forward as generic pharmaceutical products increase their market share and as consumers take a more active role in choosing their drugs from among a wide range of products with the same active pharmaceutical ingredients.


Polymers to benefit from specialty blend advances

Product versatility will be a key factor impacting product mix in excipient demand going forward, especially as specialty excipient blends play an increasingly important role in pharmaceutical formulation. Polymers -- including cellulose derivatives, povidone, starch, polyethylene glycol, acrylic polymers, and natural gums -- are expected to benefit from this trend as many of these products can function in multiple applications and are easily formulated with other excipients. These favorable characteristics will serve to offset the higher prices associated with some polymers.


Study coverage

Excipients, an upcoming industry study presents historical demand data (2003, 2008, 013) plus forecasts for 2018 and 2023 by product type and application. This study also analyzes market environment factors, evaluates company market share and profiles 47 US industry competitors.
INTRODUCTION x
I. EXECUTIVE SUMMARY 1
II. MARKET ENVIRONMENT 4
General 4
Economic Factors 5
Demographic Patterns 9
Health Care Trends 13
National Health Expenditures 14
Medical Conditions 17
Chronic Conditions 18
Acute Conditions 20
Pharmaceuticals 22
Therapeutic Class 23
Dosage Formulations 24
Distribution Classifications 26
Commercial Status 28
Regulatory Overview 29
Historical Market Trends 31
Pricing Trends 32
Foreign Trade 34
International Markets 35
III. PRODUCTS 37
General 37
Polymers 43
Cellulose Derivatives 46
Microcrystalline Cellulose (MCC) 47
Hydroxypropyl Methylcellulose (HPMC) 50
Ethyl Cellulose 54
Methyl Cellulose 55
Carboxymethylcellulose (CMC) 57
Croscarmellose Sodium 59
Other Cellulose Excipients 61
Povidone 64
Starch Compounds 67
Pregelatinized Starch 69
Sodium Starch Glycolate 71
Other Starch Excipients 73
Polyethylene Glycol 77
Acrylic Polymers 80
Other Polymers 84
Natural Gums from Seaweeds 85
Other Natural Gums 88
All Other Polymers 90
Alcohols 91
Propylene Glycol 93
Glycerin 94
Sorbitol 96
Other Alcohols 98
Mannitol 99
Other Polyol Excipients 100
All Other Alcohols 104
Minerals 104
Calcium Phosphate 107
Calcium Carbonate 109
Clay 110
Mineral Hydrocarbons 112
Silicon Dioxide 115
Titanium Dioxide 117
Other Minerals 118
Gelatin 121
Sugars 125
Lactose 127
Sucrose 129
Other Sugar Excipients 131
Other Pharmaceutical Excipients 134
Dyes & Pigments 137
Flavors 138
Surfactants 139
Acidulants 142
Antioxidants & Antimicrobials 143
All Other Compounds 145
Stearate Compounds 145
Electrolytes & Related Compounds 146
Chemical Plasticizers 146
High Intensity Sweeteners 147
Natural Fats & Oils 149
Natural Waxes 150
IV. APPLICATIONS 152
General 152
Fillers & Diluents 155
Binders 157
Suspension & Viscosity Agents 160
Coatings 162
Solvents 164
Flavoring Agents 166
Capsules 168
Disintegrants 171
Colorants 173
Lubricants & Glidants 174
Preservatives 176
Other Applications 177
V. INDUSTRY STRUCTURE 179
General 179
Market Share 181
Competitive Strategies 184
Industry Restructuring 185
Cooperative Agreements 187
Marketing & Distribution 191
Research & Development 192
Manufacturing 193
Company Profiles 194
ABITEC, see Associated British Foods
Akzo Nobel NV 195
ANGUS Chemical, see Dow Chemical
Archer-Daniels-Midland Company 196
Ashland Incorporated 198
Associated British Foods plc 201
Avantor Performance Materials Incorporated 204
BASF SE 206
Berkshire Hathaway Incorporated 209
Berwind Corporation 211
Cabot Corporation 213
Cargill Incorporated 215
Celanese Corporation 218
Colorcon, see Berwind
Corn Products International, see Ingredion
CP Kelco US, see Huber (JM)
Croda International plc 220
CyDex Pharmaceuticals, see Ligand Pharmaceuticals
Dow Chemical Company 222
DuPont (EI) de Nemours 227
Eastman Chemical Company 229
EMD Millipore, see Merck
Evonik Industries AG 231
Ferro Corporation 234
FibroGen Incorporated 235
FLAVORx Incorporated 236
FMC Corporation 237
GELITA AG 239
Generichem Corporation 240
Huber (JM) Corporation 241
Huntsman Corporation 244
Ingredion Incorporated 245
Innophos Holdings Incorporated 247
JRS Pharma, see Rettenmaier (J.) & Söhne
Kraft Foods Group Incorporated 248
Kuraray Company Limited 249
Ligand Pharmaceuticals Incorporated 250
Lubrizol, see Berkshire Hathaway
LyondellBasell Industries NV 252
Merck KGaA 253
Mutchler Incorporated 255
Nitta Gelatin Incorporated 256
NutraSweet Company 257
Nutrinova, see Celanese
P&G Chemicals, see Procter & Gamble
PB Gelatins, see Tessenderlo Group
Pfanstiehl Incorporated 258
Procter & Gamble Company 259
Rettenmaier (J.) & Söhne GmbH & Company KG 260
Roquette Frères SA 262
Royal Dutch Shell plc 265
Sasol Limited 266
Shin-Etsu Chemical Company Limited 268
Solvay SA 270
SPI Pharma, see Associated British Foods
Stepan Company 271
Tate & Lyle plc 273
Tessenderlo Group NV 275
USG Corporation 276
Wacker Chemie AG 277
Other Companies Mentioned in Study 280


LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY
Summary Table 3
SECTION II -- MARKET ENVIRONMENT
1 Macroeconomic Indicators 9
2 Population & Households 13
3 National Health Expenditures 17
4 Chronic Conditions by Type 20
5 Acute Conditions by Type 21
6 Pharmaceutical Supply & Demand 22
7 Pharmaceutical Shipments by Therapeutic Class 24
8 Pharmaceutical Shipments by Dosage Formulation 26
9 Pharmaceutical Shipments by Distribution Classification 28
10 Pharmaceutical Shipments by Commercial Status 29
11 Excipient Market, 2003-2013 32
12 Pharmaceutical Excipient Pricing 34
SECTION III -- PRODUCTS
1 Pharmaceutical Excipient Demand by Product Group 41
2 Polymer Excipient Demand by Type & Application 44
3 Cellulose Excipient Demand by Type & Application 47
4 Microcrystalline Cellulose Excipient Demand by Application 50
5 Hydroxypropyl Methylcellulose Excipient Demand
by Application 53
6 Ethyl Cellulose Excipient Demand by Application 55
7 Methyl Cellulose Excipient Demand by Application 57
8 Carboxymethylcellulose Excipient Demand by Application 59
9 Croscarmellose Sodium Excipient Demand 61
10 Other Cellulose Excipient Demand by Application 64
11 Povidone Excipient Demand by Application 67
12 Starch Excipient Demand by Type & Application 69
13 Pregelatinized Starch Excipient Demand by Application 71
14 Sodium Starch Glycolate Excipient Demand 73
15 Other Starch Excipient Demand by Application 74
16 Polyethylene Glycol Excipient Demand by Application 80
17 Acrylic Polymer Excipient Demand by Application 84
18 Other Polymer Excipient Demand by Type & Application 85
19 Alcohol Excipient Demand by Type & Application 92
20 Propylene Glycol Excipient Demand by Application 94
21 Glycerin Excipient Demand by Application 96
22 Sorbitol Excipient Demand by Application 98
23 Other Alcohol Excipient Demand by Type & Application 99
24 Mineral Excipient Demand by Type & Application 106
25 Calcium Phosphate Excipient Demand 108
26 Calcium Carbonate Excipient Demand 110
27 Clay Excipient Demand by Application 112
28 Mineral Hydrocarbon Excipient Demand by Application 115
29 Silicon Dioxide Excipient Demand by Application 117
30 Titanium Dioxide Excipient Demand 118
31 Other Mineral Excipient Demand by Application 121
32 Gelatin Excipient Demand by Application 125
33 Sugar Excipient Demand by Type & Application 126
34 Lactose Excipient Demand by Application 129
35 Sucrose Excipient Demand by Application 131
36 Other Sugar Excipient Demand by Application 134
37 Other Pharmaceutical Excipient Demand by Type & Application 136
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application 154
2 Filler & Diluent Excipient Demand by Type 157
3 Binder Excipient Demand by Type 160
4 Suspension & Viscosity Excipient Demand by Type 162
5 Coating Excipient Demand by Type 164
6 Solvent Excipient Demand by Type 166
7 Flavoring Agent Excipient Demand by Type 168
8 Capsule Excipient Demand by Type 171
9 Disintegrant Excipient Demand by Type 172
10 Colorant Excipient Demand by Type 174
11 Lubricant & Glidant Excipient Demand by Type 175
12 Preservative Excipient Demand by Type 177
13 Other Applications for Excipients by Type 178
1 US Excipient Sales by Company, 2013 180
2 Selected Acquisitions & Divestitures 187
3 Selected Cooperative Agreements 189


LIST OF CHARTS

SECTION III -- PRODUCTS
1 Excipient Demand by Product: Value & Volume, 2013 42
2 Polymer Excipient Demand: Value & Volume, 2013 45
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application, 2013 155
SECTION V -- INDUSTRY STRUCTURE
1 US Excipient Market Share, 2013 182


Read the full report:
US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
"As we've gone out into the public cloud we've seen that over time we may have lost a few things - we've lost control, we've given up cost to a certain extent, and then security, flexibility," explained Steve Conner, VP of Sales at Cloudistics,in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
"Since we launched LinuxONE we learned a lot from our customers. More than anything what they responded to were some very unique security capabilities that we have," explained Mark Figley, Director of LinuxONE Offerings at IBM, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Sanjeev Sharma Joins June 5-7, 2018 @DevOpsSummit at @Cloud Expo New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.